ClinicalTrials.gg
RecruitingNCT05959850AMBALSUpdated Sep 7, 2023

A Double-blind Randomised, Placebo-controlled Clinical Trial to Test Ambroxol Treatment in ALS

A Phase 2 interventional study of Ambroxol and Placebo in Amyotrophic Lateral Sclerosis, sponsored by The Florey Institute of Neuroscience and Mental Health. Recruiting at 5 sites in Australia. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-09-07.

Sponsored by The Florey Institute of Neuroscience and Mental Health · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Amyotrophic Lateral Sclerosis with a site in Australia — 8 open to participants now, 13 under way, 2 of them phase 3. Amyotrophic Lateral Sclerosis · Australia.

Planned enrollment
25th of 44
50 · median 63
Started
2023
with 1 other
Phase 2
17 of 44
2 open now
Primary completion
2024-06
later than 0 of 12 live
Registered
33rd of 44
by date

Among the 44 studies in Amyotrophic Lateral Sclerosis with a site in Australia, this one is the 25th largest by planned enrollment, is one of 2 that started in 2023, is one of 17 in phase 2, reaches primary completion later than 0 of the 12 other live ones, and was the 33rd registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

8 of the 44 studies in Amyotrophic Lateral Sclerosis with a site in Australia are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Amyotrophic Lateral Sclerosis with a site in Australia, or all of them as a file.
02

Study summary

Ambroxol is a simple cough medicine that is predicted to slow ALS disease progression. This study aims to investigate if ambroxol in high doses is effective in treating ALS. This study will be carried out across 5 research sites in Australia (2 NSW, 1 VIC, 1 SA and 1 TAS), where newly diagnosed ALS patients will be asked to participate. Participation will be over a 32-week period, where they will come in for a 4-week screening, 24-week treatment, and 4-week end of study safety follow-up period. The participants will receive either the placebo or drug solution that they will take three times a day, up-dosing each week until they reach the maximum dose or highest dose they can tolerate. Throughout the study their disease progression will be assessed using tests, questionnaires, and blood biomarkers.

Read the detailed description

This study is a double-blind, randomised, placebo-controlled phase 2 clinical trial, to assess the safety, tolerability and efficacy of ambroxol therapy in ALS patients by using electrophysiological and functional measures to detect preservation of motor units. The study design will have participants be randomised to either ambroxol or placebo at a 2:1 ratio (ambroxol (n=34) and placebo (n=16)). Participants randomised to the active arm will receive various doses of ambroxol in solution, taken orally, three times a day. Doses will be increased pending a safety review for each participant. The doses will be 180mg per day, 260mg per day, 540mg per day, 900mg per day, and 1260 mg per day. Each week safety bloods will be performed to assess tolerance to the dose. Participants randomised to the control arm will receive a placebo for the duration of the study. Disease progression will be assessed by the following, time to event (death, need for tracheostomy, the need for gastrostomy feeding or non-invasive ventilation support (≥12 hours a day in a 24-hour period), or ≥6-point progression (ALS functional rating score-revised).

03

Conditions studied

  • Amyotrophic Lateral Sclerosis
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must have given written before any study related assessments are performed and must be able to understand purpose of the study, including any possible risks and adverse events.
  2. ALS as diagnosed according to the recently proposed Gold Coast diagnostic criteria.
  3. First symptom of ALS less than or equal to 18 months prior to screening. The qualifying first symptoms of ALS are limited to manifestations of weakness in extremity, bulbar, or respiratory muscles. Cramps, fasciculations, or fatigue should not be taken in isolation as a first symptom of ALS.
  4. Forced vital capacity (FVC) greater than or equal to 60% of predicted value as adjusted for gender, height and age at the Screening Visit.
  5. Male or female patients aged 18 years or greater (inclusive) and less than 85 years at the time of ALS diagnosis.
  6. Able to swallow liquid.
  7. Able to perform reproducible pulmonary function tests
  8. Female patients must be or sterilized or must not be breastfeeding, have no intention to become pregnant during the study, and use acceptable methods of or abstain from intercourse.
  9. Male patients who have not had a vasectomy and confirmed zero sperm count must agree after receiving the first dose of study drug either to use acceptable methods of contraception or abstain from intercourse.
  10. If on riluzole, stable dosing for 30-days prior to screening.
  11. Pre-study ALSFRS-R progression between disease onset and screening of greater than or equal to 0.5 points/month (calculated by ALSFRS-R total score decline from 48 divided by the months since onset of ALS symptoms).

Exclusion criteria

Exclusion Criteria:

  1. Use of non-invasive ventilation (NIV) support for ALS only or gastrostomy tube at time of screening.
  2. Exposure to drug within 12-weeks prior to screening.
  3. At screening of any medically significant cardiac, pulmonary, GI, musculoskeletal, or psychiatric illness that might interfere with the patient's ability to comply with study procedures or that might confound the interpretation of clinical safety or data.
  4. Patient with a history of significant other major medical conditions based on the Investigator's judgment.
  5. Based on the investigator's judgment, patients who may have difficulty complying with the protocol and/or any study procedures.
  6. Any person who is an employee or an Investigator or Sponsor, or an immediate relative of an Investigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Experimental: Active

    Ambroxol taken 3x daily. Variation in doses as follow-up progresses. For detailed information, see Intervention Description.

    Drug: Ambroxol

  • Placebo comparator
    Placebo Comparator: Control

    Glucose Placebo, taken 3x daily. Variation in doses as follow-up progresses. For detailed information, see Intervention Description.

    Drug: Placebo

Interventions

  • Participants in the study will receive varying doses of ambroxol in solution, 3 times per day. Doses will be increased pending a safety review, up to a maximum of 1260mg/day. Blood tests will be conducted weekly to assess tolerance. Compliance will be monitored by returning used bottles. The study will last 32 weeks, including 24 weeks of drug administration and follow-up visits. After the final follow-up, there will be an end of study safety visit occurring 4 weeks later. The total time of participation will be 32 weeks. This includes a screening visit up to 4 weeks prior to Baseline, then a Baseline visit, followed by 24 weeks of follow-up (3x in clinic follow-up visits). These 24 weeks will be the drug administration period, meaning that the total duration of drug administration is 24 weeks. Following this drug administration and follow-up period, there will be an EoS safety-follow up visit that will occur 4 weeks after the final follow-up visit (28 weeks from baseline).

    Also known as: Ambroxol Hydrochloride

  • DrugPlacebo

    Participants randomised to the control arm will receive a placebo for the duration of the study. The placebo will look and taste like ambroxol, but will have no active ingredient. Participants will not be told which arm they have been randomised to. The placebo will primarily be a glucose solution, however it will also have flavouring (e.g. bitters) and colouring, so as to make it look and taste like ambroxol, to maintain blinding.

06

What researchers measure

Primary outcomes

  1. Time to event

    Time to event (death, need for tracheostomy, the need for gastrostomy feeding or non-invasive ventilation (NIV) support (greater than or equal to 12 hours a day in a 24-hour period), or greater than or equal to 6-point progression on the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS)) This will be measured by patient medical records, and the completion of the ALSFRS by investigators.

    Time frame: Time to event for a maximum of 24 weeks from baseline

Secondary outcomes

  1. ALS functional rating score-revised (ALSFRS-R)

    Change in ALSFRS-R Score

    Time frame: 24 weeks from Baseline

  2. Motor unit number estimation (MUNIX)

    Change in MUNIX values

    Time frame: 24 weeks from Baseline

  3. Split Hand Index (SI)

    Change in SI value

    Time frame: 24 weeks from Baseline

  4. Neurophysiology Index (NPI)

    Change in NPI Value

    Time frame: 24 weeks from Baseline

  5. Kings staging system

    Change in Kings stage

    Time frame: 24 weeks from Baseline

  6. Muscle strength assessment as measured by the Medical Research Council (MRC) Scale for Muscle Strength

    Change in Muscle strength, where Grade 0 is no visible contraction and Grade 5 is Normal

    Time frame: 24 weeks from Baseline

  7. Respiratory function (FVC) as measure by a Spirometer

    Change in FVC

    Time frame: 24 weeks from Baseline

  8. Survival

    Overall survival rate

    Time frame: 24 weeks from Baseline

  9. Serum NFL levels

    Change in Serum NFL Levels

    Time frame: 24 weeks from Baseline

  10. Assessment of Quality of Life (AQoL)

    Change in AQoL score

    Time frame: 24 weeks from Baseline

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — No plan to have individual participant data available to other researchers

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Jun 2024, 12 months after the start.

Of 37 non-industry phase 2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 41. This study's planned 12 months is below that.

Counting every sponsor, half of 73 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2023
First posted
Jul 25, 2023
StartActual
Jun 13, 2023
Primary completionEst.
Jun 2024
CompletionEst.
Dec 2024
Last update
Sep 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05959850
Lead sponsor
The Florey Institute of Neuroscience and Mental Health
Collaborators
Mobius Medical Pty Ltd., The University of Queensland
Responsible party
Sponsor
First posted
Jul 25, 2023
Start date
Jun 13, 2023
Primary completion
Jun 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Sep 7, 2023

Study contacts

Bradley Turner
Contact
bradley.turner@florey.edu.au
+61 3 9035 6521
Bradley Turner
study chair · The Florey Institute of Neuroscience and Mental Health
Steve Vucic
principal investigator · Concord Repatriation General Hospital
Matthew Kiernan
principal investigator · Brain and Mind Centre (The University of Sydney)
Susan Mathers
principal investigator · Calvary Health Care Bethlehem
David Schultz
principal investigator · Flinders Medical Centre
Lauren Giles
principal investigator · Launceston General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ambroxol

Start the discussion